Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
This market has seen a flurry of activity, as shown by a review of the latest agents.
The key is using the right dose on the right patient at the right time.
The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).
Outside of vaccines, these underutilized therapies are the best defense against severe disease.
New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.
The latest article from SIDP illustrates the challenges of area under the curve (AUC) implementation and offers insights for strategies and resources to overcome them.
New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
Christina Lee, PharmD, and Julia Donahue, PharmD, analyzed 533 encounters revealing a 27.1% readmission rate in immunocompromised patients versus 14.1% in non-immunocompromised patients.
Biocontainment, including the most recent threat of highly pathogenic avian influenza, demands we continue to finance research, and continue cooperation with important organizations like the WHO.
De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Here is a review of the literature for this class of antibiotics.
Although COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.
De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
How pharmacists can use shared decision-making to improve antibiotic use.
Findings from a recent phase 3 trial show promising results for the approval of ziresovir in the treatment of respiratory syncytial virus in infants.
With antimicrobial drug shortages expected to continue globally, developing mitigation strategies is essential to prevent complications, including antimicrobial resistance.
Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
These skills are as critical as ever, and younger clinicians and learners need them to communicate and work professionally.
Biologics have become a novel treatment in recurrent C. difficile.
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.